N w-hydroxy-L-arginine as a novel ethnic specific indicator of estrogen-negative breast cancer

Srinidi Mohan; Nancy Moua; Lisa Harding

doi:10.1007/s00726-016-2301-5

N ^w-hydroxy-L-arginine as a novel ethnic specific indicator of estrogen-negative breast cancer

Amino Acids. 2016 Nov;48(11):2693-2698. doi: 10.1007/s00726-016-2301-5. Epub 2016 Aug 9.

Authors

Srinidi Mohan¹, Nancy Moua², Lisa Harding²

Affiliations

¹ Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, 04103, USA. smohan@une.edu.
² Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, 04103, USA.

PMID: 27503558
DOI: 10.1007/s00726-016-2301-5

Abstract

As a heterogeneous disease, breast cancer can be divided into distinct subtypes. Among the two major subsets of estrogen receptor-negative (ER^-) and ER-positive (ER⁺) tumors, the ER^- is a more aggressive subtype, more difficult to treat, has greater ethnic disparity concerns, worse prognosis, and almost twice the risk of mortality. We provide here a fundamental delineation of N ^w-hydroxy-L-arginine as a sensitive and reliable ethnic specific indicator for ER^- breast cancer early-prognosis (United States provisional patent application number 62232816).

Keywords: Breast cancer; Estrogen-negative; Inflammatory nitric oxide synthase; N w-hydroxy-L-arginine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Arginine / analogs & derivatives*
Arginine / metabolism*
Biomarkers, Tumor / metabolism*
Breast Neoplasms / ethnology*
Breast Neoplasms / metabolism*
Female
Humans
MCF-7 Cells
Receptors, Estrogen*

Substances

Biomarkers, Tumor
Receptors, Estrogen
Arginine